Comprehensive List of Preventative Migraine Headache Medications Without Significant Drug-drug Interactions

Overview

Journal Front Neurol

Specialty Neurology

Date 2024 Dec 30

PMID 39734637

Authors

Jay Dave

Ian Hakkinen

Pengfei Zhang

Affiliations

Soon will be listed here.

Abstract

Background/objective: Preventive medications are crucial in migraine prevention. In cases of refractory migraine headaches, multiple medications may be required. We seek to identify a comprehensive list of preventive migraine headache medications that can be used as two, three, and four drug combinations without drug-drug interactions.

Methods: We compiled a list of prevention medications from Szperka et al.'s "Migraine Care in the Era of COVID-19" as well as American Headache Society's 2018 and 2021 "Consensus Statements on Integrating New Migraine Treatments into Clinical Practice." We obtained all possible two to four combinations of prevention medications through this list. We then filtered out all combinations containing at least one interaction based on DrugBank database and also identified least to most interacting medications.

Results: A total of 26 unique prevention medications are identified. This results in a total of 325 combinations of two preventives, 2,600 combinations of three preventives, and 14,950 combinations of four preventives. There are a total of 124, 146, and 0 non-interacting two, three, and four preventive combinations, respectively. All except 16 combinations of pick-twos can be placed within a pick-three combinations. The resulting distinct non-interacting medications can be represented by a condensed list of 162 unique combinations of medications. CGRP antagonists, Botulinum toxin A, melatonin, and candesartan are least interacting.

Conclusion: This list of migraine preventive medications without drug-drug interactions is a useful tool for clinicians seeking to manage refractory headaches more effectively by implementing an evidence-based polypharmacy.

References

Haanes K, Chan K, MaassenVanDenBrink A . Comment on "A second trigeminal CGRP receptor: function and expression of the AMY1 receptor". Ann Clin Transl Neurol. 2016; 3(4):307-8. PMC: 4818740. DOI: 10.1002/acn3.286. View

Hamon M, Blier P . Monoamine neurocircuitry in depression and strategies for new treatments. Prog Neuropsychopharmacol Biol Psychiatry. 2013; 45:54-63. DOI: 10.1016/j.pnpbp.2013.04.009. View

Li S, Wang T, Wang R, Dai X, Chen Q, Li R . Melatonin enhances antinociceptive effects of delta-, but not mu-opioid agonist in mice. Brain Res. 2005; 1043(1-2):132-8. DOI: 10.1016/j.brainres.2005.02.067. View

Aurora S, Dodick D, Turkel C, DeGryse R, Silberstein S, Lipton R . OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia. 2010; 30(7):793-803. DOI: 10.1177/0333102410364676. View

Okuma H, Iijima K, Yasuda T, Tokuoka K, Kitagawa Y . Preventive effect of cyproheptadine hydrochloride in refractory patients with frequent migraine. Springerplus. 2013; 2:573. PMC: 3824712. DOI: 10.1186/2193-1801-2-573. View

Lionetto L, Borro M, Curto M, Capi M, Negro A, Cipolla F . Choosing the safest acute therapy during chronic migraine prophylactic treatment: pharmacokinetic and pharmacodynamic considerations. Expert Opin Drug Metab Toxicol. 2016; 12(4):399-406. DOI: 10.1517/17425255.2016.1154042. View

Villalon C, Olesen J . The role of CGRP in the pathophysiology of migraine and efficacy of CGRP receptor antagonists as acute antimigraine drugs. Pharmacol Ther. 2009; 124(3):309-23. DOI: 10.1016/j.pharmthera.2009.09.003. View

Mendelsohn F, Jenkins T, Berkovic S . Effects of angiotensin II on dopamine and serotonin turnover in the striatum of conscious rats. Brain Res. 1993; 613(2):221-9. DOI: 10.1016/0006-8993(93)90902-y. View

Ailani J, Burch R, Robbins M . The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice. Headache. 2021; 61(7):1021-1039. DOI: 10.1111/head.14153. View

10.

Jensen B, OConnell T, Simpson P . Alpha-1-adrenergic receptors: targets for agonist drugs to treat heart failure. J Mol Cell Cardiol. 2010; 51(4):518-28. PMC: 3085055. DOI: 10.1016/j.yjmcc.2010.11.014. View

11.

Imig C, Min S, Krinner S, Arancillo M, Rosenmund C, Sudhof T . The morphological and molecular nature of synaptic vesicle priming at presynaptic active zones. Neuron. 2014; 84(2):416-31. DOI: 10.1016/j.neuron.2014.10.009. View

12.

Gleiter C, Morike K . Clinical pharmacokinetics of candesartan. Clin Pharmacokinet. 2002; 41(1):7-17. DOI: 10.2165/00003088-200241010-00002. View

13.

Lee M, Al-Karagholi M, Reuter U . New migraine prophylactic drugs: Current evidence and practical suggestions for non-responders to prior therapy. Cephalalgia. 2023; 43(2):3331024221146315. DOI: 10.1177/03331024221146315. View

14.

Pomes L, Guglielmetti M, Bertamino E, Simmaco M, Borro M, Martelletti P . Optimising migraine treatment: from drug-drug interactions to personalized medicine. J Headache Pain. 2019; 20(1):56. PMC: 6734220. DOI: 10.1186/s10194-019-1010-3. View

15.

Asghar M, Becerra L, Larsson H, Borsook D, Ashina M . Calcitonin Gene-Related Peptide Modulates Heat Nociception in the Human Brain - An fMRI Study in Healthy Volunteers. PLoS One. 2016; 11(3):e0150334. PMC: 4798403. DOI: 10.1371/journal.pone.0150334. View

16.

Naumann M, Lowe N, Kumar C, Hamm H . Botulinum toxin type a is a safe and effective treatment for axillary hyperhidrosis over 16 months: a prospective study. Arch Dermatol. 2003; 139(6):731-6. DOI: 10.1001/archderm.139.6.731. View

17.

Tsai Y, Kotiya A, Kiris E, Yang M, Bavari S, Tessarollo L . Deubiquitinating enzyme VCIP135 dictates the duration of botulinum neurotoxin type A intoxication. Proc Natl Acad Sci U S A. 2017; 114(26):E5158-E5166. PMC: 5495235. DOI: 10.1073/pnas.1621076114. View

18.

Edvardsson B . Atenolol in the prophylaxis of chronic migraine: a 3-month open-label study. Springerplus. 2013; 2:479. PMC: 3786076. DOI: 10.1186/2193-1801-2-479. View

19.

Purkiss J, Welch M, Doward S, Foster K . Capsaicin-stimulated release of substance P from cultured dorsal root ganglion neurons: involvement of two distinct mechanisms. Biochem Pharmacol. 2001; 59(11):1403-6. DOI: 10.1016/s0006-2952(00)00260-4. View

20.

Kaytser V, Zhang P . Non-interacting, Non-opioid, and Non-barbiturate Containing Acute Medication Combinations in Headache: A Pilot Combinatorics Approach Based on DrugBank Database. Front Neurol. 2021; 12:632830. PMC: 7925628. DOI: 10.3389/fneur.2021.632830. View